ANPCF - ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
(NewsDirect)
ANGLE PLC chief executive Andrew Newlandjoins Proactive's Stephen Gunnion with details of a supplieragreement with AstraZeneca PLC to develop an androgen receptor (AR)detection assay to enhance prostate cancer studies.
With a contract value of £550,000, theproject is scheduled for completion in the first quarter of nextyear.
Newland said the agreement isan extension of a prior arrangement to develop a methodology fordetecting CTC micronuclei and will use ANGLE's innovativeParsortix system. Successful development of this AR assay is expectedto bolster the use of the Parsortix system in clinical oncology,particularly for assessing the efficacy of prostate cancertherapies.
The discussion also touched upon the potentialbenefits of this development for ANGLE, suggesting it mightsignificantly enhance the company's operations and marketposition.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.